Pasireotide
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cushings Disease
Conditions
Cushings Disease
Trial Timeline
Mar 28, 2013 → Jul 10, 2023
NCT ID
NCT02310269About Pasireotide
Pasireotide is a pre-clinical stage product being developed by Recordati for Cushings Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02310269. Target conditions include Cushings Disease.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06295952 | Phase 2 | Recruiting |
| NCT02310269 | Pre-clinical | Completed |
Competing Products
3 competing products in Cushings Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pasireotide with or without cabergoline | Novartis | Phase 2 | 52 |
| osilodrostat + LCI699 matching placebo | Novartis | Phase 3 | 77 |
| LCI699 | Novartis | Phase 2 | 52 |